GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Shiller PE Ratio

FibroGen (FibroGen) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Shiller PE Ratio Historical Data

The historical data trend for FibroGen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Shiller PE Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

FibroGen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of FibroGen's Shiller PE Ratio

For the Biotechnology subindustry, FibroGen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Shiller PE Ratio falls into.



FibroGen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

FibroGen's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, FibroGen's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.57/129.4194*129.4194
=-0.570

Current CPI (Dec. 2023) = 129.4194.

FibroGen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.344 99.695 -0.447
201406 0.383 100.560 0.493
201409 -0.710 100.428 -0.915
201412 -0.856 99.070 -1.118
201503 -0.780 99.621 -1.013
201506 0.830 100.684 1.067
201509 -0.740 100.392 -0.954
201512 -0.850 99.792 -1.102
201603 -0.450 100.470 -0.580
201606 0.350 101.688 0.445
201609 -0.380 101.861 -0.483
201612 -0.490 101.863 -0.623
201703 -0.480 102.862 -0.604
201706 -0.460 103.349 -0.576
201709 -0.320 104.136 -0.398
201712 -0.270 104.011 -0.336
201803 -0.500 105.290 -0.615
201806 -0.280 106.317 -0.341
201809 -0.500 106.507 -0.608
201812 0.230 105.998 0.281
201903 -0.530 107.251 -0.640
201906 1.260 108.070 1.509
201909 -0.570 108.329 -0.681
201912 -1.120 108.420 -1.337
202003 -0.890 108.902 -1.058
202006 -0.950 108.767 -1.130
202009 0.350 109.815 0.412
202012 -0.640 109.897 -0.754
202103 -0.780 111.754 -0.903
202106 -1.450 114.631 -1.637
202109 0.540 115.734 0.604
202112 -1.450 117.630 -1.595
202203 -0.680 121.301 -0.726
202206 -0.780 125.017 -0.807
202209 -0.980 125.227 -1.013
202212 -0.700 125.222 -0.723
202303 -0.810 127.348 -0.823
202306 -0.900 128.729 -0.905
202309 -0.650 129.860 -0.648
202312 -0.570 129.419 -0.570

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (NAS:FGEN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


FibroGen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158